Benzinga··Vandana SinghBioNTech Shares Tumble as COVID Vaccine Demand Wanes, Major Restructuring Looms
BioNTech shares fell 3% on Q1 revenue miss as COVID vaccine sales decline. Company announced €500M cost-cutting restructuring targeting 2029 completion.
BNTXrestructuringcost savings